InhaleRx Closes Entitlement Offer and Placement, Securing $857,730
InhaleRx Limited has successfully closed its entitlement offer and placement, raising $857,730 to support the clinical development of inhaled treatments targeting cancer pain and mental health conditions.
- Entitlement offer raised $107,730 before costs
- Placement secured $750,000 with some tranches pending shareholder approval
- Total funds received or committed amount to $857,730
- New shares and options to be allotted and commence trading by end of December
- Capital raise supports development of therapies for breakthrough cancer pain, panic disorder, and treatment-resistant depression
Capital Raising Update
InhaleRx Limited, an Australian clinical-stage drug developer, has announced the successful close of its recent capital raising initiatives. The company’s entitlement offer, which closed on 17 December 2025, raised $107,730 before costs, while a concurrent placement secured $750,000 in funding. Together, these efforts have generated a total of $857,730 in funds received or committed, providing a meaningful boost to InhaleRx’s financial resources as it advances its drug development programs.
The entitlement offer involved the issuance of new shares and attaching options, with allotment scheduled for 23 December 2025 and expected trading of the new shares commencing on 30 December. Despite a shortfall of approximately $139,938 under the entitlement offer, InhaleRx is working with its lead manager, Peak Asset Management, to place this balance within three months, maintaining momentum in its capital raising strategy.
Placement Details and Shareholder Approval
The placement was structured in two tranches, with $427,500 received under Tranche 1 and a committed balance of $172,500 expected imminently. A further $150,000 is anticipated under Tranche 2, which remains subject to shareholder approval. This phased approach reflects a cautious but optimistic capital strategy, balancing immediate funding needs with governance requirements.
New shares and options issued under the placement will further expand the company’s capital base, enabling InhaleRx to accelerate its clinical programs. The company’s board expressed gratitude to participating shareholders for their ongoing support, underscoring the importance of this funding round in sustaining development activities.
Strategic Focus on Inhaled Therapies
InhaleRx is focused on developing rapid-onset inhaled therapies addressing significant unmet needs in pain management and mental health. Its lead candidates include IRX-211 for breakthrough cancer pain, IRX-616a for panic disorder, and SRX-25 targeting treatment-resistant depression. The company aims to leverage expedited regulatory pathways, such as the FDA’s 505(b)(2) process, to bring these therapies to market efficiently.
The capital raised will support ongoing clinical trials and regulatory activities, positioning InhaleRx to capitalize on a substantial economic opportunity. The targeted indications represent areas where current treatments are often inadequate or carry dependency risks, highlighting the potential impact of InhaleRx’s innovations.
Looking Ahead
With the entitlement offer allotment imminent and placement funds largely secured, InhaleRx is poised to continue its clinical development trajectory into 2026. The company’s ability to convert committed placements into actual funds and secure shareholder approvals will be critical milestones to watch in the coming months.
Bottom Line?
InhaleRx’s latest capital raise lays the groundwork for advancing inhaled therapies, but shareholder approvals and clinical progress remain key to unlocking value.
Questions in the middle?
- Will shareholder approval be secured for the remaining placement tranches?
- How soon can InhaleRx progress its clinical trials with the new funding?
- What are the timelines for regulatory submissions and potential FDA approval?
